Viatris (VTRS) investor relations material

Business performance and growth outlook

• North America saw 3% growth, driven by generics and complex injectable launches, with operational growth trending above 2%.

• Cost savings program underway, targeting $120 million in net savings this year to improve operating leverage.

• Free cash flow exceeded $2 billion in Q1, with expectations for acceleration through 2030, supporting strategic flexibility.

• Balanced capital allocation includes continued dividends, opportunistic share repurchases, and significant investment in business development (BD).

• Generics remain a core part of the business, with a focus on complex products and selective global opportunities.

Product pipeline and launch strategy

• Upcoming launches in Japan include Effexor for anxiety and pitolisant, with Nefecon expected next year, aiming to return Japan to growth by 2028.

• North America anticipates launches in the contraceptive patch portfolio, targeting over $300 million in peak sales.

• Fast-acting meloxicam, a non-opioid acute pain treatment, could reach $500 million in lifetime sales, with material contribution expected from 2027.

• New launches are expected to accelerate overall growth to a 3%-4% top-line CAGR by 2030.

Business development and capital allocation

• Approximately half of $11 billion in capital return may be used for BD, with a focus on assets that fit strategically and can build cornerstone franchises.

• BD is expected to contribute $1–1.5 billion in revenue and $0.5 billion in adjusted EBIT over the next 3–4 years.

• Priorities include strengthening regional segments and expanding the innovative business in the U.S.